Palmitoyl tetrapeptide-7Cosmetic ingredient
Palmitoyl tetrapeptide-7 appears in cosmetic blends, including combinations marketed as Matrixyl 3000. Its proposed role concerns signalling associated with inflammation and the skin matrix.
What is Palmitoyl tetrapeptide-7?
Palmitoyl tetrapeptide-7 is a cosmetic peptide used in blends such as Matrixyl 3000, alongside palmitoyl tripeptide-1. Its proposed role concerns inflammatory signalling and the skin matrix.
How it works
Laboratory explanations focus on signals that influence the skin environment. Changing such a signal is different from treating an inflammatory skin disease.
Effects studied
Appearance of lines and texture in peptide blends
The retained formulation study concerns a combined product. A result for the blend cannot show how much this individual ingredient contributed, while delivery remains dependent on the formulation. 1 2
Evidence: Combined-formula clinical lead and delivery research context.
What does the evidence show?
The retained sources include a cosmetic formulation study and a review relevant to peptide delivery. They do not establish a stand-alone treatment effect for this ingredient.
The biological proposal
Laboratory research on this peptide often concerns inflammatory signals that influence the skin environment. Reducing one of those signals does not establish that a product treats an inflammatory skin condition. That claim would require a study of the condition, using a defined product and an outcome that matters to the person using it.
Why Matrixyl names can be confusing
Matrixyl 3000 generally refers to a blend containing palmitoyl tetrapeptide-7 and palmitoyl tripeptide-1. It is not the same ingredient as palmitoyl pentapeptide-4, also associated with the Matrixyl family of names. Evidence should follow the precise blend rather than the shared branding.
What a combined-formula study establishes
If a serum contains several peptides and other skincare ingredients, an improvement can support that serum under the tested conditions. It cannot tell us how much each ingredient contributed. Delivery through the skin is another formulation-dependent question highlighted by the retained research context. 1 2
Keep the cosmetic role clear
Improving texture or the appearance of lines does not establish treatment of eczema, rosacea or another disease. Disease claims require different evidence. A finished formula can still cause sensitivity or irritation, even if its ingredients are described as calming.
Safety & status
A cosmetic formula can still irritate sensitive skin. These appearance claims do not establish treatment of eczema, rosacea or another skin disease.
Country and product status
This page describes a cosmetic ingredient and its research context. Permitted claims and product availability in Germany and Switzerland need a local check. An ingredient listing does not establish approval to treat a medical condition.
Frequently asked questions
Is Matrixyl 3000 the same as the original Matrixyl peptide?
No. Matrixyl 3000 generally combines this ingredient with palmitoyl tripeptide-1; the original Matrixyl ingredient is palmitoyl pentapeptide-4.
Does an anti-inflammatory mechanism make it an eczema treatment?
No. A disease-treatment claim requires evidence in that condition with a defined product and meaningful outcomes.
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Palmitoyl tetrapeptide-7: paper 10.1111/jocd.15849 Research reference · Retained archive reference; not independently checked for this draft.
- Palmitoyl tetrapeptide-7: paper 10.1111/ics.12770 Research reference · Retained archive reference; not independently checked for this draft.
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.